Recovery from immunosuppression-related disorders in humans and animals by IP-PA1, an edible lipopolysaccharide

Anticancer Res. 2010 Aug;30(8):3113-8.


Immunopotentiator from Pantoea agglomerans 1 (IP-PA1), an edible lipopolysaccharide (LPS) derived from symbiotic bacteria in crops, is a promising immunomodulator. It activates macrophages and protects from chemotherapeutic agent-induced growth inhibition in macrophages in vitro. We showed the immune-recovery effects of IP-PA1 in a chicken model of dexamethasone-induced stress in which IP-PA1 inhibited thymic and bursal atrophy and improved antibody production in response to vaccination. Furthermore, we showed IP-PA1 improved survival of melanoma-bearing, doxorubicin-treated mice, although not directly affecting the proliferation of melanoma cells, dominantly through the improvement of host antitumor immunity. These results suggest that IP-PA1 could have other possible applications in the treatment of various immunosuppression-related disorders in humans and animals.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dexamethasone / administration & dosage
  • Humans
  • Immune System Diseases / chemically induced
  • Immune System Diseases / drug therapy*
  • Immune System Diseases / etiology
  • Immunosuppressive Agents / administration & dosage
  • Lipopolysaccharides / therapeutic use*
  • Mice
  • Neoplasms / immunology
  • Neoplasms / physiopathology
  • Stress, Physiological


  • Immunosuppressive Agents
  • Lipopolysaccharides
  • lipopolysaccharide IP-PA1, Pantoea agglomerans
  • Dexamethasone